12-30-04

THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-006; A-415H)

PATENT

In re Application of: Fisher et al.		
Serial No.: 09/882,735)	Before the Examiner:	C. O'Hara
Filed: June 15, 2001	Group Art Unit: 1646	
For: Truncated Soluble Tumor Necrosis)		
Factor Type-I and Type-II Receptors)		
Mail Stop Issue Fee		
Commissioner for Patents		

Sir:

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

- 1. We are transmitting herewith the attached papers for the above-described patent application: Amendment under 37 C.F.R. § 1.312 and return postcard.
- 2. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.
- 3. CERTIFICATE OF MAILING BY "EXPRESS MAIL" UNDER 37 C.F.R. 1.10: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "Express Mail Post Office to Addressee" in an envelope addressed to: Mail Stop Issue Fee, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450, on December 29, 2004.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: December 29, 2004

Donald L. Zuhn, Ph.D

Reg. No. 48,710

THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 02-006; A-415H) **PATENT** cation of: Fisher et al. **Before the Examiner:** E. O'Hara Serial No.: 09/882,735 **Group Art Unit:** 1646 Filed: June 15, 2001 **Truncated Soluble Tumor Necrosis** For: Factor Type-I and Type-II Receptors) Mail Stop Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir:

AMENDMENT UNDER 37 C.F.R. § 1.312

Applicants respectfully request that the following additional amendments be entered prior to issuance of the above-described patent application pursuant to 37 C.F.R. §1.312.

<u>Amendments to the Claims</u>: Pursuant to 37 C.F.R. § 1.121, Applicants present a complete listing of the claims, including marked up versions of all currently amended claims, at pages 2-8.

Remarks: Applicants' Remarks begin on page 9 of this paper.